Skip to main content

Table 4 Costs and outcomes measured

From: Policy models for preventative interventions in cardiometabolic diseases: a systematic review

Authors name

Costs

Outcomes

Discounting

Direct

healthcare

costs

Indirect costs

Programme/implementation costs

Disease cases/

event

LY/LE

QALY/

DALY

ACER/ICER/

NMB

Moran et al. (2008) [32]

-

-

-

-

Moran et al. (2010) [33]

N/R

N/R

N/R

-

-

-

N/R

Bibbins-Domingo et al. (2010) [34]

-

-

-

-

-

Wang et al. (2012) [35]

-

-

-

-

Basu et al. (2013) [36]

-

-

-

-

Konfino et al. (2013) [37]

N/R

N/R

N/R

-

-

-

N/R

Basu et al. (2014) [38]

-

-

-

-

-

N/R

Collins et al. (2014) [39]

-

-

Mason et al. (2014) [40]

-

-

-

Lewsey et al. (2015) [41]

N/R

N/R

N/R

-

-

N/R

Manyema et al. (2015) [42]

-

-

-

Wilcox et al. (2014) [43]

-

-

Collins et al. (2015) [44]

-

-

-

-

Lawson et al. (2016) [45]

N/R

N/R

N/R

-

-

Sánchez-Romero et al. (2016) [46]

-

-

-

-

N/R

Wang et al., (2016) [47]

-

-

-

Breeze et al. (2017) [48]

Pandya et al. (2017) [49]

N/R

N/R

N/R

-

-

-

N/R

Mozaffarian et al. (2018) [50]

-

-

Riveros et al. (2018) [51]

N/R

N/R

N/R

-

-

N/R

Schönbach et al. (2019) [52]

-

-

-

N/R

Huang et al. (2019) [53]

-

-

Salgado et al. (2019) [54]

N/R

N/R

N/R

-

-

-

N/R

Wilde et al. (2019) [55]

-

-

Broeks et al. (2020) [56]

-

-

-

Lee et al. (2020) [57]

-

-

Liu et al. (2020) [58]

-

Salgado et al. (2020) [59]

-

-

-

-

N/R

Dehmer et al. (2020) [60]

-

-

-

-

-

Shangguan et al. (2021) [61]

-

-

Thomas et al. (2022) [62]

-

-

Lou et al. (2023) [63]

-

-

  1. N/R Not related, LE Life expectancy, LY Life year, DALY Disability-adjusted life year, QALY Quality-adjusted life year, ACER Average cost effectiveness ratio, ICER Incremental cost-effectiveness ratio, NMB Net monetary benefit